Related references
Note: Only part of the references are listed.Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Cholesterol Homeostasis Modulates Platinum Sensitivity in Human Ovarian Cancer
Daniela Criscuolo et al.
CELLS (2020)
Gene Expression Indicates Altered Immune Modulation and Signaling Pathway Activation in Ovarian Cancer Patients Resistant to Topotecan
Otilia Menyhart et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis
Dongqing Yan et al.
CLINICAL CANCER RESEARCH (2019)
FOXO3a Reverses the Cisplatin Resistance in Ovarian Cancer
Mudan Lu et al.
ARCHIVES OF MEDICAL RESEARCH (2018)
A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer
Kathleen N. Moore et al.
FUTURE ONCOLOGY (2018)
Inhibition of MUS81 improves the chemical sensitivity of olaparib by regulating MCM2 in epithelial ovarian cancer
Ailing Zhong et al.
ONCOLOGY REPORTS (2018)
Jabl/COPS5 as a Novel Biomarker for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Human Cancer
Guohong Liu et al.
FRONTIERS IN PHARMACOLOGY (2018)
Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer
Ying Chen et al.
CLINICAL CANCER RESEARCH (2017)
Competitive reactions among glutathione, cisplatin and copper-phenanthroline complexes
Enzo Cadoni et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2017)
COPS5 inhibition arrests the proliferation and growth of serous ovarian cancer cells via the elevation of p27 level
Hongqin Zhang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
Cisplatin resistance and opportunities for precision medicine
Lauren Amable
PHARMACOLOGICAL RESEARCH (2016)
COPS5 amplification and overexpression confers tamoxifen-resistance in ERα-positive breast cancer by degradation of NCoR
Renquan Lu et al.
NATURE COMMUNICATIONS (2016)
Molecular mechanisms of cisplatin cytotoxicity in acute promyelocytic leukemia cells
Sanjay Kumar et al.
ONCOTARGET (2015)
p53 protein aggregation promotes platinum resistance in ovarian cancer
Y. Yang-Hartwich et al.
ONCOGENE (2015)
Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: A meta-analysis
Suk-Joon Chang et al.
GYNECOLOGIC ONCOLOGY (2013)
Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients
Balazs Gyoerffy et al.
ENDOCRINE-RELATED CANCER (2012)
clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters
Guangchuang Yu et al.
OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY (2012)
Myofibrillogenesis regulator 1 (MR-1) is a novel biomarker and potential therapeutic target for human ovarian cancer
Renquan Lu et al.
BMC CANCER (2011)
Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer
Meng Li et al.
BMC MEDICAL GENOMICS (2009)
Role of copper transporters in the uptake and efflux of platinum containing drugs
R Safaei
CANCER LETTERS (2006)
Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals
S Ishida et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Share Paper
